Lista de obras - Michel Attal - Dominio Público Uruguay

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

artículo científico publicado en 2016

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

artículo científico publicado en 2018

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

artículo científico publicado en 2010

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

scientific article published on 13 October 2009

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

artículo científico publicado en 2014

All transplantation-eligible patients with myeloma should receive ASCT in first response.

artículo científico publicado en 2014

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

artículo científico publicado en 2020

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

artículo científico publicado en 2012

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

artículo científico publicado en 2009

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

artículo científico publicado en 2010

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

artículo científico publicado en 2010

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

artículo científico publicado en 2011

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

artículo científico publicado en 2013

Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2014

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

scientific article published on 03 May 2019

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

artículo científico publicado en 2013

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

artículo científico publicado en 2002

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

artículo científico

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

artículo científico

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2013

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

artículo científico publicado en 2019

Deciphering the chronology of copy number alterations in Multiple Myeloma

artículo científico publicado en 2019

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

artículo científico publicado en 2013

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

artículo científico publicado en 2019

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

artículo científico publicado en 2019

Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation.

artículo científico publicado en 2014

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

artículo científico publicado en 2011

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

artículo científico publicado en 2014

Frontline therapy of multiple myeloma.

artículo científico

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2007

Genomics of Multiple Myeloma.

artículo científico publicado en 2017

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

artículo científico publicado en 2020

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

artículo científico publicado en 2014

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the Europea

artículo científico publicado en 2014

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

artículo científico publicado en 2018

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

artículo científico publicado en 2019

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

artículo científico publicado en 2017

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

artículo científico publicado en 2017

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

artículo científico publicado en 2012

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

artículo científico publicado en 2017

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Logic programming reveals alteration of key transcription factors in multiple myeloma

artículo científico publicado en 2017

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

artículo científico publicado en 2018

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

artículo científico publicado en 2012

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

scientific article published on 27 July 2006

Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.

artículo científico publicado en 2014

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

artículo científico publicado en 2010

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

artículo científico

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

artículo científico

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

artículo científico publicado en 2013

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2018

Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients

artículo científico publicado en 2012

Prognostic significance of copy-number alterations in multiple myeloma

artículo científico publicado en 2009

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

artículo científico publicado en 2012

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

artículo científico publicado en 2015

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

artículo científico publicado en 2016

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

artículo científico publicado en 2016

Stem-cell transplantation in multiple myeloma

artículo científico publicado en 2005

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

artículo científico publicado en 2002

The current landscape of multiple myeloma treatment

artículo científico publicado en 2008

The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.

artículo científico publicado en 2013

The translocation t(4;14) can be present only in minor subclones in multiple myeloma

artículo científico publicado en 2013

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

artículo científico publicado en 2013

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

artículo científico publicado en 2010

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years

artículo científico publicado en 2014

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

artículo científico publicado en 2015

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT

artículo científico publicado en 2014

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

artículo científico publicado en 2016

Lista de obras de Michel Attal

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

All transplantation-eligible patients with myeloma should receive ASCT in first response.

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Deciphering the chronology of copy number alterations in Multiple Myeloma

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Frontline therapy of multiple myeloma.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Genomics of Multiple Myeloma.

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

IMWG consensus on maintenance therapy in multiple myeloma

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the Europea

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Logic programming reveals alteration of key transcription factors in multiple myeloma

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients

Prognostic significance of copy-number alterations in multiple myeloma

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

Stem-cell transplantation in multiple myeloma

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

The current landscape of multiple myeloma treatment

The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.

The translocation t(4;14) can be present only in minor subclones in multiple myeloma